NASDAQ:INSY | Gaining Green

Biotech Bullish Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), SIGA Technologies (NASDAQ:SIGA), Insys Therapeutics Inc (NASDAQ:INSY), Insmed Incorporated (NASDAQ:INSM), Egalet Corp (NASDAQ:EGLT) Achillion Pharmaceuticals (NASDAQ:ACHN), Director Gary E. Frashier sold 55,000 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $8.00, for a total transaction of $440,000.00. Achillion Pharmaceuticals (NASDAQ:ACHN), weekly performance is 18.30%. On last trading day company shares ended up $8.08. Analysts mean target price for the company is $8.22. Achillion Pharmaceuticals (NASDAQ:ACHN), distance from 50-day simple moving average (SMA50) is 132.64%. SIGA Technologies (NASDAQ:SIGA), advanced 5.25% in last trading session and ended the day on $2.90. SIGA, return on assets is -10.40%. SIGA Technologies (NASDAQ:SIGA), quarterly performance is -7.19%. Insys Therapeutics Inc (NASDAQ:INSY), Director John N. Kapoor acquired 5,000 shares of the stock on the open market in a transaction that occurred on Friday, June 13th. The stock was purchased at an average cost of $25.44 per share, with a total value of $127,200.00. Following the purchase, the director now directly owns 15,991 shares of the company’s stock, valued at approximately $406,811. Insys Therapeutics Inc (NASDAQ:INSY), shares moved up 5.30% in last trading session and was closed at $29.80, while trading in range of $28.12 – 31.84. Insys Therapeutics Inc (NASDAQ:INSY), year to date (YTD) performance is 15.46%. Insmed Incorporated (NASDAQ:INSM)’s shares increased 33.65% to $16.66 on no official news. The company on May 29 announced the appointment of David R. Brennan to its Board of Directors. Mr. Brennan has more than 37 years of experience in the pharmaceutical industry and was formerly the Chief Executive Officer of AstraZeneca PLC. From 2006 to 2012 Mr. Brennan served as Chief Executive Officer of AstraZeneca, a leading global pharmaceutical company with more than $27 billion in revenue and 60,000 employees in 2012. Mr. Brennan started his career in sales at Merck and Co. and quickly ascended into management roles at Merck. Insmed Incorporated (NASDAQ:INSM), ended the last trading day at $18.80. Company weekly volatility is calculated as 7.99% and price to cash ratio as 7.29. Insmed Incorporated (NASDAQ:INSM), showed a positive weekly performance of 49.80%. Canaccord Genuity initiated coverage on shares of Egalet Corp (NASDAQ:EGLT), in a research report sent to investors on Wednesday morning, Analyst RN reports. The firm issued a buy rating and a $20.00 price target on the stock. Egalet Corp (NASDAQ:EGLT), weekly performance is 19.05%. On last trading day company shares ended up $15.06. Analysts mean target price for the company is $22.25. Egalet Corp (NASDAQ:EGLT), distance from 50-day simple moving average (SMA50) is 22.88%.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Director Gary E. Frashier sold 55,000 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $8.00, for a total transaction of $440,000.00. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), weekly performance is 18.30%. On last trading day company shares ended up $8.08. Analysts mean target price for the company is $8.22. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), distance from 50-day simple moving average (SMA50) is 132.64%.

SIGA Technologies, Inc. (NASDAQ:SIGA), advanced 5.25% in last trading session and ended the day on $2.90. SIGA, return on assets is -10.40%. SIGA Technologies, Inc. (NASDAQ:SIGA), quarterly performance is -7.19%.

Insys Therapeutics Inc (NASDAQ:INSY), Director John N. Kapoor acquired 5,000 shares of the stock on the open market in a transaction that occurred on Friday, June 13th. The stock was purchased at an average cost of $25.44 per share, with a total value of $127,200.00. Following the purchase, the director now directly owns 15,991 shares of the company’s stock, valued at approximately $406,811. Insys Therapeutics Inc (NASDAQ:INSY), shares moved up 5.30% in last trading session and was closed at $29.80, while trading in range of $28.12 – 31.84. Insys Therapeutics Inc (NASDAQ:INSY), year to date (YTD) performance is 15.46%.

Insmed Incorporated (NASDAQ:INSM)’s shares increased 33.65% to $16.66 on no official news. The company on May 29 announced the appointment of David R. Brennan to its Board of Directors. Mr. Brennan has more than 37 years of experience in the pharmaceutical industry and was formerly the Chief Executive Officer of AstraZeneca PLC. From 2006 to 2012 Mr. Brennan served as Chief Executive Officer of AstraZeneca, a leading global pharmaceutical company with more than $27 billion in revenue and 60,000 employees in 2012. Mr. Brennan started his career in sales at Merck and Co. and quickly ascended into management roles at Merck. Insmed Incorporated (NASDAQ:INSM), ended the last trading day at $18.80. Company weekly volatility is calculated as 7.99% and price to cash ratio as 7.29. Insmed Incorporated (NASDAQ:INSM), showed a positive weekly performance of 49.80%.

Canaccord Genuity initiated coverage on shares of Egalet Corp (NASDAQ:EGLT), in a research report sent to investors on Wednesday morning, Analyst RN reports. The firm issued a buy rating and a $20.00 price target on the stock. Egalet Corp (NASDAQ:EGLT), weekly performance is 19.05%. On last trading day company shares ended up $15.06. Analysts mean target price for the company is $22.25. Egalet Corp (NASDAQ:EGLT), distance from 50-day simple moving average (SMA50) is 22.88%.

Tag: NASDAQ:INSY